Insulet (NASDAQ:PODD) Sets New 52-Week Low - Time to Sell?

Shares of Insulet Co. (NASDAQ:PODD - Get Free Report) hit a new 52-week low during trading on Wednesday . The company traded as low as $245.66 and last traded at $252.29, with a volume of 720882 shares traded. The stock had previously closed at $251.27.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on PODD shares. Wells Fargo & Company set a $322.00 price objective on Insulet in a research report on Monday, April 28th. Piper Sandler raised their price target on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Wolfe Research lowered shares of Insulet from an "outperform" rating to a "peer perform" rating in a research report on Tuesday. Barclays lifted their target price on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Finally, Royal Bank of Canada started coverage on Insulet in a report on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target for the company. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $293.94.

Insulet Stock Up 2.7 %

The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The business has a 50-day simple moving average of $257.51 and a two-hundred day simple moving average of $262.48. The stock has a market capitalization of $18.05 billion, a P/E ratio of 44.39, a PEG ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The business had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Equities research analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the firm's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This trade represents a 36.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.47% of the company's stock.

Institutional Investors Weigh In On Insulet

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in shares of Insulet during the fourth quarter valued at approximately $248,806,000. GAMMA Investing LLC boosted its position in Insulet by 27,298.6% in the 1st quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock valued at $1,744,100,000 after buying an additional 661,717 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Insulet in the 4th quarter valued at $69,433,000. Alecta Tjanstepension Omsesidigt bought a new stake in shares of Insulet during the fourth quarter worth $53,184,000. Finally, Artisan Partners Limited Partnership lifted its stake in shares of Insulet by 24.1% during the fourth quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier's stock valued at $201,073,000 after acquiring an additional 149,524 shares during the period.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.